Adaptive Biotechnologies Corp (NASDAQ: ADPT) is 29.61% higher on its value in year-to-date trading and has touched a low of $2.28 and a high of $8.95 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ADPT stock was last observed hovering at around $8.03 in the last trading session, with the day’s loss setting it -0.26%.
Currently trading at $7.77, the stock is -4.43% and 3.80% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.57 million and changing -3.24% at the moment leaves the stock 46.32% off its SMA200. ADPT registered 94.74% gain for a year compared to 6-month gain of 73.05%.
The stock witnessed a 5.43% loss in the last 1 month and extending the period to 3 months gives it a 18.99%, and is -4.78% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.47% over the week and 8.93% over the month.
Adaptive Biotechnologies Corp (ADPT) has around 619 employees, a market worth around $1.15B and $178.96M in sales. Profit margin for the company is -89.12%. Distance from 52-week low is 240.79% and -13.18% from its 52-week high. The company has generated returns on investments over the last 12 months (-38.50%).
with sales reaching $42.28M over the same period.The EPS is expected to grow by 14.13% this year, but quarterly earnings will post 18.86% year-over-year. Quarterly sales are estimated to grow 0.96% in year-over-year returns.
The shares outstanding are 147.77M, and float is at 143.70M with Short Float at 6.11%.
The top institutional shareholder in the company is VIKING GLOBAL INVESTORS LP with over 29.99 million shares valued at $108.58 million. The investor’s holdings represent 20.3466 of the ADPT Shares outstanding. As of 2024-06-30, the second largest holder is RUBRIC CAPITAL MANAGEMENT LP with 14.0 million shares valued at $50.68 million to account for 9.4971 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 11.66 million shares representing 8.0007 and valued at over $42.22 million, while MATRIX CAPITAL MANAGEMENT COMPANY, LP holds 7.8504 of the shares totaling 11.57 million with a market value of $41.89 million.
Adaptive Biotechnologies Corp (ADPT) Insider Activity
The most recent transaction is an insider sale by LO FRANCIS, the company’s Chief People Officer. SEC filings show that LO FRANCIS sold 20,875 shares of the company’s common stock on Mar 05 ’25 at a price of $6.99 per share for a total of $0.15 million. Following the sale, the insider now owns 0.33 million shares.
Adaptive Biotechnologies Corp disclosed in a document filed with the SEC on Mar 05 ’25 that BOBULSKY SUSAN (Chief Commercial Officer, MRD) sold a total of 26,023 shares of the company’s common stock. The trade occurred on Mar 05 ’25 and was made at $6.98 per share for $0.18 million. Following the transaction, the insider now directly holds 0.35 million shares of the ADPT stock.
Still, SEC filings show that on Mar 05 ’25, BENZENO SHARON (Chief Commercial Ofc Imm Med) disposed off 44,665 shares at an average price of $6.98 for $0.31 million. The insider now directly holds 392,723 shares of Adaptive Biotechnologies Corp (ADPT).
